<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998217</url>
  </required_header>
  <id_info>
    <org_study_id>Rem-ESWL-Pancreas</org_study_id>
    <nct_id>NCT01998217</nct_id>
  </id_info>
  <brief_title>Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal shock wave lithotripsy (ESWL) of pancreatic stones has been described as an
      effective approach for stone drainage and pain relief, and general or epidural anesthesia has
      been reported for such procedure. Single infusion of remifentanil has been described in ESWL
      of urinary stones, but it has never been described in ESWL of pancreatic stones. Moreover,
      single infusion of remifentanil might induce several complications, such as postoperative
      nausea and vomiting. The investigators attended to investigated whether combination of
      flurbiprofen with remifentanil reduced remifentanil dose and attenuated the complications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue score of pain</measure>
    <time_frame>During ESWL procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular responses including blood pressure and heart rate</measure>
    <time_frame>During ESWL procedure</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>within 24 hours after ESWL procedure</time_frame>
    <description>The side effects including postoperative nausea and vomiting, as well as pruritus.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pancreatic Stone Disease</condition>
  <arm_group>
    <arm_group_label>Rem group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group receive single infusion of remifentanil with target concentration infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flur group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group receive both infusion of flurbiprofen and remifentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.</description>
    <arm_group_label>Rem group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen and remifentanil</intervention_name>
    <description>Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.</description>
    <arm_group_label>Flur group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18-65 years

          -  ASA I-II

          -  ESWL indication was met

        Exclusion Criteria:

          -  patients with hypertension

          -  patients compromised in cardiopulmonary function

          -  patients undergoing ESWL for the second or more times
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology, Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Jia-feng Wang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>extracorporeal shock wave lithotripsy</keyword>
  <keyword>remifentanil</keyword>
  <keyword>flurbiprofen</keyword>
  <keyword>pancreatic stone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

